Life-Threatening Contraceptive-Related Pulmonary Embolism in a 14-Year-Old Girl with Hereditary Thrombophilia

Maja Hellfritzsch

Erik Lerkevang Grove

Corresponding Author: Maja Hellfritzsch, e-mail: mmsimonsen@health.sdu.dk

Conflict of interest: None declared

Patient: Female, 14
Final Diagnosis: Pulmonary embolism
Symptoms: Chest pain • dyspnea • syncope
Medication: Combined oral contraceptives
Clinical Procedure: —
Specialty: Internal Medicine

Objective: Adverse events of drug therapy

Background: The prothrombotic effect of combined oral contraceptives (COCs) is well-established, with a 3–6-fold increased risk of VTE compared to non-users. When initiation of COCs is considered, it is therefore of paramount importance to carefully evaluate all other potential risk factors for VTE. Based on a case of life-threatening COC-associated pulmonary embolism in a girl heterozygous for the prothrombin G20210A mutation and with a family history of thrombotic disease, we discuss the importance of assessing not just the genotype but also the phenotype when considering initiation of COCs in patients with thrombophilia.

Case Report: A 14-year-old girl presented with acute onset of chest pain and dyspnea followed by syncope. She was hypoxic and hemodynamically compromised at admission. Computed tomography pulmonary angiography revealed a large central “saddle” pulmonary embolism causing nearly total occlusion of the right pulmonary artery, and several minor peripheral embolisms bilaterally. She was successfully treated with thrombolysis (alteplase) followed by aPTT-adjusted heparin infusion until adequate anticoagulation with warfarin was achieved. Two years earlier, the patient had been found heterozygote for the prothrombin G20210A mutation, and 9 months before admission she had initiated use of second-generation COCs.

Conclusions: Hereditary thrombophilia and a family history of early-onset venous thromboembolism (VTE) each pose an increased risk of VTE and should be considered as separate, irreversible risk factors. Other contraceptive methods should be used when treatment with COCs is expected to result in an unacceptable high risk of VTE.

MeSH Keywords: Contraceptives, Oral, Hormonal • Thrombophilia • Venous Thrombosis

Full-text PDF: http://www.amjcaserep.com/abstract/index/idArt/894721

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License
Background

Combined oral contraceptives (COCs) are associated with a 3-6 times higher risk of venous thromboembolism (VTE) compared to non-users [1,2]. Likewise, hereditary thrombophilia increases VTE risk, some more than other [3]. Persons heterozygous of the prothrombin G20210A mutation have a 3-fold increased risk of VTE [4]. Accordingly, this thrombophilia is generally classified as a minor risk factor for thrombosis [5] and, therefore, some consider this only as a relative, not absolute, contraindication for COC-use [6,7].

However, based on a case of massive pulmonary embolisms in a COC-using girl heterozygous for the prothrombin G20210A mutation and with familial disposition for thrombotic disease, we aim to emphasize the importance of assessing not just the genotype but also the phenotype when considering initiation of COCs in patients with thrombophilia.

Case Report

A 14-year-old, normal-weight, non-smoking, white girl presented with acute onset of chest pain and dyspnea followed by syncope. She was transported to the hospital by ambulance, where she was found hypoxic (saturation 87%), tachycardic (heart rate 125), and hypotensive (systolic BP <100 mmHg). Acute echocardiography was performed (Video 1) and revealed dilatation of the right ventricle (“D-configuration”), pulmonary hypertension (tricuspid regurgitation pressure gradient 50 mm Hg), and reduced pulmonary blood flow. A highly elevated D-dimer (16.1 mg/L) and a moderate increase in Troponin T (243 ng/L) was found. Computed tomography pulmonary angiography revealed a large central “saddle” pulmonary embolism causing nearly total occlusion of the right pulmonary artery (Figure 1), and several minor peripheral embolisms bilaterally. Physical examination was without clinical signs of deep venous thrombosis.

Because the patient was hemodynamically compromised, thrombolytic treatment with alteplase was initiated and followed by aPTT-adjusted heparin infusion. After termination of the infusion, low molecular weight heparin was initiated and continued until adequate anticoagulation with warfarin was achieved. Clinical treatment effect was observed within a few hours, and echocardiography on day 2 confirmed that the pulmonary pressure was reduced. At discharge on day 3, the patient was hemodynamically stable (BP 120/70 mm Hg, HR 85, and saturation 98%) with only a minor sensation of respiratory distress.

Due to several cases of both arterial and venous thrombosis at young age in at least 2 generations of the family, the patient had been tested for hereditary thrombophilia 2 years earlier; she was heterozygote for the prothrombin G20210A mutation. Due to severe menstrual bleedings, she had initiated use of second-generation COCs containing 250 µg norgestimate and 35 µg ethinylestradiol once daily 9 months before admission. The use of this contraceptive was discontinued at admission, and she was strictly advised to never resume treatment.

Discussion

COC-users heterozygote for the prothrombin G20210A mutation have been found to have a 7–10-fold increased risk of VTE, with the risk being highest early in the course of COC use [8–10]. This combination thus results in an at least additive and maybe even a synergistic prothrombotic effect. Whether the risk is further increased in individuals who additionally have
a thrombophilic phenotype is not known. However, a positive family history, defined as a documented VTE in a first-degree relative, is an established individual risk factor for VTE (3-fold VTE risk) [9] and is therefore assumed to also be important in individuals with hereditary thrombophilia [5].

Current WHO guidelines advise against use of COCs in females with any known prothrombotic mutation [11]. However, several clinicians advocate that an individualized risk assessment where several risk factors, including the specific thrombophilia, age, and individual and family history of VTE, should be taken into consideration when counseling females with thrombophilia about contraceptive use [5,7,10]. Low-risk thrombophilia alone, such as the prothrombin G20210A mutation, is considered by some to be a relative, but not absolute, contraindication for COC use [6,7]. However, as emphasized by this case report, it is important to consider not just the inherited genotype but also the inherited phenotype when evaluating the risk of thrombosis. Since a prothrombotic genotype does not necessarily result in a prothrombotic phenotype, and vice versa, they should be considered as separate and potentially interacting risk factors [3,5,10]. Unprovoked venous thrombosis in a first-degree relative occurring before 50 years of age indicates a strongly thrombophilic phenotype, and should therefore be considered a relative contraindication for COC use, regardless of the patient’s genotype [5].

The family history of our patient indicated a strongly thrombophilic phenotype, which in combination with the prothrombotic effects of both the mutation and COCs resulted in a life-threatening major thrombotic event. Future treatment with COCs or other types of estrogen-containing hormonal preparations (i.e., hormone replacement therapy) is contraindicated.

Current evidence does not support anticoagulant therapy of higher intensity or longer duration than normal when treating VTE patients with the prothrombin G20210A mutation [5]. Our patient was thus started on warfarin with target INR 2.0-3.0 and planned duration of 12 months [13]. A non-vitamin K antagonist oral anticoagulant (NOAC; dabigatran, rivaroxaban, or apixaban) might be an equally effective and safe treatment compared to warfarin in this patient [13,14]. However, patients with pulmonary embolism treated with thrombolysis were not included in phase III trials on NOACs, and data on long-term prophylaxis and treatment of VTE with NOACs are warranted.

**Conclusions**

Initiation of COCs should be based on individualized risk assessment with all potential risk factors for VTE, including both genotype (if available) and phenotype, taken into account. Other contraceptive methods should be considered in patients with an increased risk of VTE.

**Conflicts of interest**

None relevant to this manuscript.

**References:**

1. Lidegaard Ø, Nielsen LH, Skovlund CW et al: Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogens: Danish cohort study, 2001-9. BMJ, 2011; 343: d6423
2. Vinogradova Y, Coupland C, Hippisley-Cox J. Use of combined oral contraceptives and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ, 2015; 350: h2135
3. Bauer KA: The thrombophilias: well-defined risk factors with uncertain therapeutic implications. Ann Intern Med, 2001; 135: 367–73
4. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM: A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood, 1996; 88: 3698–703
5. Baglin T, Gray E, Greaves M et al: Clinical guidelines for testing for heritable thrombophilia. Br J Haematol, 2010; 149: 209–20
6. Van Vlijmen EFV, Veezer NIGA, Middeldorp S et al: Thrombotic risk during oral contraceptive use and pregnancy in women with factor V Leiden or prothrombin mutation: a rational approach to contraception. Blood, 2011; 118: 2055–61
7. The Danish Society of Thrombosis and Hemostasis. Guidelines for testing for thrombophilia [Internet]. Available from: URL: http://dhst.dk/pdf/Rapporter_retningslinjer/01_TROMBOFIILpdf [in Danish]
8. Wu O, Robertson L, Langhorne P et al: Oral contraceptives, hormone replacement therapy, thrombophilia and risk of venous thromboembolism: a systematic review. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study. Thromb Haemost, 2005; 94: 17–25
9. Emmerich J, Rosendaal FR, Cattaneo M et al: Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism – pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous Thromboembolism. Thromb Haemost, 2001; 86: 809–16
10. Konkle BA: Counseling of women with thrombophilia. Thromb Res, 2005; 115(Suppl.1): 44–46
11. World Health Organization. Medical eligibility criteria for contraceptive use [Internet]. 2009. Available from: URL: http://whqlibdoc.who.int/publications/2010/9789241563888_eng.pdf?ua=1
12. Trenor CC, Chung RJ, Michelson AD et al: Hormonal contraception and thrombotic risk: a multidisciplinary approach. Pediatrics, 2011; 127: 347–57
13. Konstantinides SV, Torbicki A, Agnelli G et al: 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J, 2014; 35: 3033–69, 3069a–3069k
14. Van der Hulle T, Kooiman J, den Exter PL et al: Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost, 2014; 12: 320–28